August 6, 2018 10:04 AM EDT

Protagonist raises $22M to revive PTG-100; Paratek's antibiotic shows non-inferiority

Brittany Meiling

→ Protagonist Therapeutics {PTGX}, a tiny public company in Newark, CA, has inked a securities purchase deal totaling $22 million in shares to sort out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Protagonist raises $22M to revive PTG-100; Paratek's antibiotic shows non-inferiority

Brittany Meiling

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Protagonist raises $22M to revive PTG-100; Paratek's antibiotic shows non-inferiority